GLP-1 drugs are reshaping employer health costs

GLP-1 receptor agonists are a class of drugs originally developed for type 2 diabetes. They mimic the hormone GLP-1, which is released after eating and suppresses appetite. In recent years they have also been approved for obesity. Brand names including Ozempic, Wegovy, Mounjaro and Zepbound have become household names.

US employers cover a large share of their employees’ healthcare costs. A report from STAT News describes how the rise of GLP-1 drugs is forcing employers to decide whether to cover these expensive medicines fully, partially, or not at all. Monthly costs per user can reach hundreds or thousands of dollars.

Cover or not: a difficult call

Studies show that GLP-1 drugs do more than reduce weight. They also lower the risk of cardiovascular disease, sleep apnoea and related conditions. In the long term, that could reduce overall medical costs. On the other hand, the drugs are expensive, and many patients regain weight if they stop taking them without adequate support.

A separate legal dispute is also playing out around the 340B drug pricing programme, a US scheme that gives hospitals and clinics discounts on medicines. Insurers and employers are fighting over how those discounts are applied, adding another layer of complexity to GLP-1 pricing.

Why this matters for longevity

For longevity science, GLP-1 drugs are relevant because obesity and metabolic disease accelerate aging. Drugs that reduce weight and markers of inflammation could in theory slow biological aging, though that has not yet been directly demonstrated for GLP-1 agents. The coverage debate shows that access to such interventions can be as much of a barrier as the science itself.

Read the original article